#Biotech Companies

J&J exec says biotechs aren’t ‘necessarily on sale’ even after a challenging 2021

The comments made by a Johnson & Johnson JNJ, +1.31% executive earlier this week about biotechnology valuations calls attention to the struggling biotech sector. “It’s really hard to say whether there’s been a capitulation or a recognition that values have come down,” J&J CFO Joseph Wolk said Tuesday, according to a FactSet transcript of the company’s fourth-quarter earnings call. “We probably need to see a little bit longer period of that. I don’t think things are out there necessarily on sale.”
Picture for J&J exec says biotechs aren’t ‘necessarily on sale’ even after a challenging 2021

Investment in Healthcare Start-Ups in Catalonia Reaches €238 Million

The Catalan biotech sector is unstoppable. Investment in healthcare startups in the region continues to rise and has once again surpassed the $223million (€200 million) barrier for the second year in a row, despite the pandemic. In total, they have raised $265.5 million (€238 million) in investment, the highest figure on record to date. Funding from venture capital has been the main driver of this growth, accumulating more than $208 million (€187 million) and representing 79% of the total capital raised, a figure that has tripled compared to 2019, according to a Biocat report.
Picture for Investment in Healthcare Start-Ups in Catalonia Reaches €238 Million

LifeMD: High Growth Telehealth Company Nearing Profitability

LifeMD's DTC telehealth business is a market leader and is poised to show substantial growth after the recent launch of virtual primary care services and expansion into asthma. As the market continues to collapse and interest rates continue to go up, I have focused my efforts on finding companies that...

Alector, Inc: A Newer Biotech Company With Big Potential

Biotech companies have seen an economic boom lately thanks to the COVID-19 Pandemic and the need for effective treatments. Alector, Inc. (NASDAQ: ALEC) is one of the freshest faces in the biotech industry, having only been taken public in February of 2019. While many of its successful counterparts have thrown themselves into the pandemic-driven fray, Alector has made its mark by offering potential revolutionary advances to the treatment of neurodegenerative diseases, a lucrative pocket in the medical market desperate for advancement. A deal with GlaxoSmithKline (NYSE: GSK) in July 2021 for a breakthrough monoclonal antibody treatment saw stock prices soar. However, since that announcement, Alector has underperformed, seeing its stock prices fall back down to earth despite showing promising earnings results in Q3 2021.
Worcester Business Journal

Mass. biopharma funding reaches record-breaking $14B

In 2021, Massachusetts-based biopharma companies received a record-breaking total of $13.66-billion in venture capital funding, a 70% increase compared to the year prior, according to a report released Wednesday. The Massachusetts Biotechnology Council, a Cambridge-based nonprofit, released its 2021 Massachusetts Biopharma Funding Report detailing the state’s economic growth as an...
Boston Globe

Massachusetts biopharma firms raised a record $13.7 billion in venture capital last year

Massachusetts drug makers continued to bring in huge amounts of venture capital last year, setting a record for money raised, according to the industry trade group. Local biopharma firms attracted $13.7 billion in 2021, up 70 percent from a year prior, the Massachusetts Biotechnology Council said in a report Wednesday. The group said “the power of biopharma companies to change the course of human health through vaccines and therapeutics” is continuing to attract money.

Two income-oriented strategies to protect and grow wealth in the market

Kevin Simpson, founder and chief investment officer at Capital Wealth Planning. No matter what 2022 reveals, the time is always right to make smart, long-term investments to build wealth and protect what you have. It's vital to have a strategy and disciplined approach — with an eye on the long...

Cramer’s love at first sight: Occidental Petroleum is ‘the only oil stock I don’t like here’

EQRx Inc.: “What some companies have to do is they have to buy biotech companies. That’s the kind of company that has to be bought. It shouldn’t be independent.”. DigitalOcean Holdings: “It’s selling at 190 times earnings. I don’t recommend anything north of 50 times earnings. It’s just my new rule of discipline to get me through this tough time.”

Continuous processing and CGTs: MilliporeSigma on CDMO trends for 2022

BioProcess Insider spoke virtually with MilliporeSigma’s head of Process Solutions Andrew Bulpin about his predictions for the company and the CDMO space in 2022. The life sciences services division of Merck KGaA, MilliporeSigma, has been steadily increasing its contract development manufacturing organization (CDMO) services through a string of investments and expansions.

Pharmaron Beijing says profit rose amid US, UK expansion

Pharmaron Beijing, a China-based pharmaceutical research company led by billionaire Lou Boliang, expects profits earned in the year to December 31 to jump as much as 45% to 1.7 billion yuan, or about $265 million. amid rising revenues and international expansion. Revenue is expected to grow 43% to 46% by...